Annual Current Liabilities
$80.68 M
+$28.77 M+55.43%
December 31, 2023
Summary
- As of February 7, 2025, RNA annual total current liabilities is $80.68 million, with the most recent change of +$28.77 million (+55.43%) on December 31, 2023.
- During the last 3 years, RNA annual current liabilities has risen by +$66.09 million (+453.10%).
- RNA annual current liabilities is now at all-time high.
Performance
RNA Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$91.33 M
+$7.12 M+8.46%
September 1, 2024
Summary
- As of February 7, 2025, RNA quarterly total current liabilities is $91.33 million, with the most recent change of +$7.12 million (+8.46%) on September 1, 2024.
- Over the past year, RNA quarterly current liabilities has increased by +$42.62 million (+87.48%).
- RNA quarterly current liabilities is now at all-time high.
Performance
RNA Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
RNA Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +55.4% | +87.5% |
| 3 y3 years | +453.1% | +307.4% |
| 5 y5 years | +1647.8% | - |
RNA Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +172.0% | at high | +207.9% |
| 5 y | 5-year | at high | +688.2% | at high | +792.3% |
| alltime | all time | at high | +1647.8% | at high | +792.3% |
Avidity Biosciences Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $91.33 M(+8.5%) |
| Jun 2024 | - | $84.21 M(+12.4%) |
| Mar 2024 | - | $74.95 M(-7.1%) |
| Dec 2023 | $80.68 M(+55.4%) | $80.68 M(+65.6%) |
| Sep 2023 | - | $48.72 M(+7.7%) |
| Jun 2023 | - | $45.24 M(-5.9%) |
| Mar 2023 | - | $48.09 M(-7.4%) |
| Dec 2022 | $51.91 M | $51.91 M(+21.7%) |
| Sep 2022 | - | $42.67 M(+26.7%) |
| Jun 2022 | - | $33.69 M(+8.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $30.92 M(+4.3%) |
| Dec 2021 | $29.66 M(+103.3%) | $29.66 M(+32.3%) |
| Sep 2021 | - | $22.42 M(+37.2%) |
| Jun 2021 | - | $16.34 M(-6.7%) |
| Mar 2021 | - | $17.51 M(+20.1%) |
| Dec 2020 | $14.59 M(+42.5%) | $14.59 M(+6.6%) |
| Sep 2020 | - | $13.68 M(+17.7%) |
| Jun 2020 | - | $11.62 M(+2.5%) |
| Mar 2020 | - | $11.34 M(+10.8%) |
| Dec 2019 | $10.24 M(+121.8%) | $10.24 M |
| Dec 2018 | $4.62 M | - |
FAQ
- What is Avidity Biosciences annual total current liabilities?
- What is the all time high annual current liabilities for Avidity Biosciences?
- What is Avidity Biosciences annual current liabilities year-on-year change?
- What is Avidity Biosciences quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Avidity Biosciences?
- What is Avidity Biosciences quarterly current liabilities year-on-year change?
What is Avidity Biosciences annual total current liabilities?
The current annual current liabilities of RNA is $80.68 M
What is the all time high annual current liabilities for Avidity Biosciences?
Avidity Biosciences all-time high annual total current liabilities is $80.68 M
What is Avidity Biosciences annual current liabilities year-on-year change?
Over the past year, RNA annual total current liabilities has changed by +$28.77 M (+55.43%)
What is Avidity Biosciences quarterly total current liabilities?
The current quarterly current liabilities of RNA is $91.33 M
What is the all time high quarterly current liabilities for Avidity Biosciences?
Avidity Biosciences all-time high quarterly total current liabilities is $91.33 M
What is Avidity Biosciences quarterly current liabilities year-on-year change?
Over the past year, RNA quarterly total current liabilities has changed by +$42.62 M (+87.48%)